Therapeutic Asset Ratings
436 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
yl-13027
cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
P1/2
CC
(45)
yl201
cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
P1/2
CC
(45)
Budigalimab
cancer
AbbVie
P1
CC
(42)
ibi321
cancer
Innovent Biologics (Suzhou) Co. Ltd.
P1
CC
(42)
kl340399
cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
P1
CC
(42)
ZELUVALIMAB
cancer
Amgen
P1
CC
(42)
Zimberelimab
cancer
Compugen Ltd
P1
CC
(42)
BMS-986213
cancer
Bristol-Myers Squibb
P1/2
CC
(42)
BMS-986408
cancer
Bristol-Myers Squibb
P1/2
CC
(42)
ibi334
cancer
Innovent Biologics (Suzhou) Co. Ltd.
P1/2
CC
(42)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .KAPPA.-CHAIN, DIMER
cancer
Cantargia AB
P1/2
CC
(42)
mk-1200
cancer
Merck Sharp & Dohme LLC
P1/2
CC
(42)
sph4336
cancer
Shanghai Pharmaceuticals Holding Co., Ltd
P1/2
CC
(42)
gk01
cancer
Beijing Geekgene Technology Co., LTD
P1
CC
(41)
hf50
cancer
HighField Biopharmaceuticals Corporation
P1
CC
(41)
Ovv-01
cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P1
CC
(41)
ak129
cancer
Akeso
P1/2
CC
(40)
Alk-N001 For
cancer
Zhejiang Anglikang Pharmaceutical Co., Ltd.
P1/2
CC
(40)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
cancer
BOE Technology Group Co., Ltd.
P1/2
CC
(40)
Amt-253 For
cancer
Multitude Therapeutics Inc.
P1/2
CC
(40)
Askg915
cancer
AskGene Pharma, Inc.
P1/2
CC
(40)
asp1570
cancer
Astellas Pharma Global Development, Inc.
P1/2
CC
(40)
Atg-016
cancer
Shanghai Antengene Corporation Limited
P1/2
CC
(40)
Autologous Cd8+ T-Cells, Transduced With Mage-A1 Directed Tcr
cancer
T-knife GmbH
P1/2
CC
(40)
bat1006 for
cancer
Bio-Thera Solutions
P1/2
CC
(40)
Showing 101 to 125 of 436 assets
Previous
Page 5 of 18
Next
